LONDON BROKER RATINGS: RBC cuts National Grid; Citigroup cuts South32
28th May 2025 09:36
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - Stock prices in Europe ended largely higher on Tuesday, building on a confident start to the week, while equities in London also got in on the action following Monday's public holiday. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer. Read More
(Alliance News) - London's FTSE 100 is called higher on Tuesday following a bank holiday-lengthened weekend, as Nato members are expected to raise defence spending to 5% of output. Read More
AstraZeneca PLC - Cambridge-based pharmaceutical and biotechnology company - Says Chief Executive Officer Pascal Soriot has been appointed a director of Santa Clara, California-based laboratory software and services company Agilent Technologies Inc, effective immediately. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said it has completed its acquisition of Belgian biotechnology firm EsoBiotec SA, bolstering its cell therapy capabilities with a platform that could significantly accelerate cancer treatment delivery. Read More
AstraZeneca PLC - Cambridge-based pharmaceutical and biotechnology company - Phase 3b Batura trial shows statistically significant and clinically meaningful improvements in mild asthma in patients treated with Airsupra (albuterol and budesonide) than albuterol alone. Compared to placebo, Airsupra significantly reduces the risk of a severe symptom exacerbation by 47%. Patients treated with airsupra have 63% lower exposure to total systemic corticosteroids over the treatment period compared with albuterol-alone, reducing risks from cumulative exposure to SCS which include type 2 diabetes, depression and anxiety, renal impairment, cataracts, cardiovascular disease, pneumonia and fractures. Read More
(Alliance News) - The FTSE 100 pushed higher on Friday, ending the week on a strong note, and now at the level it roughly stood at prior to US President Donald Trump's 'liberation day' tariff melee. Read More
(Alliance News) - London's FTSE 100 outperformed European peers, though a share price fall for oil majors and a host of other shares that went ex-dividend kept a lid on the blue-chip index's progress. Read More
(Alliance News) - AstraZeneca PLC on Monday announced that its medicine Trixeo Aerosphere has been approved by the UK Medicines & Healthcare Products Regulatory Agency with "an innovative, next-generation propellant with near-zero global warming potential". Read More
(Alliance News) - London opened in the green on Monday, as the US and China agree a 90-day pause on tariffs and the UK prepares to host European ministers for talks on Russia. Read More
(Alliance News) - AstraZeneca PLC on Friday said it has received positive data from a trial evaluating Imfinzi as a treatment for patients with high-risk non-muscle-invasive bladder cancer. Read More
(Alliance News) - European stocks opened higher on Thursday, with the FTSE 100 registering only a minor gain, however, as investors digest Wednesday's Federal Reserve decision and look ahead to a probable Bank of England rate cut. Read More
(Alliance News) - The FTSE 100 ended a 16-day winning streak on Wednesday, ahead of interest rate decisions in the US and UK, weighed by weak pharmaceutical and telecoms stocks. Read More
(Alliance News) - Stock prices in London were weaker on Wednesday, with some pre-Federal Reserve decision nerves and geopolitical tensions hurting sentiment. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said it has received positive high-level results from its latest trial evaluating Enhertu in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Read More
(Alliance News) - London's FTSE 100 gave back a fraction of its recent progress early Wednesday, despite some optimism on the tariff front, ahead of a US interest rate decision later. Read More
(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults. Read More
(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, kicking off the week following an extended bank holiday weekend, as Germany prepares to swear in its new chancellor and UK consumer confidence hits a new low. Read More
(Alliance News) - AstraZeneca PLC on Friday reported that its triple-combination asthma treatment Breztri Aerosphere met all primary endpoints in two late-stage clinical trials, raising the potential to improve treatment options for patients whose condition is not controlled by current therapies. Read More